Title for MeetingAbstracts
Alphabetical listing of titles
-
Fighting HIV/AIDS social stigma through mobilization of youth in the Gaza Strip - Palestine.
-
Fighting HIV/AIDS through media: A case of ACYC radio and television programs.
-
Fighting prejudice with information: launching the AIDS news agency.
-
Fighting Stigma in Tanzania against PLHA's still an issue.
-
Fighting stigma on HIV/AIDS.
-
Fighting stigma using PLWAS support groups.
-
Fighting stigmatisation.
-
Fighting the spread of HIV/AIDS by preventing syringe reuse.
-
Fighting the tide: creating a community based response to women and HIV/AIDS in the Maritimes.
-
Fighting the violence against sex workers in a rural province of Cambodia by strengthening peer support groups.
-
Figthting stigma on HIV/AIDS.
-
Filamentous Phage for Producing Antibody Responses Focused against B2.1, an HIV-1 Vaccine Lead Peptide.
-
Filgrastim (G-CSF) use is associated with prolonged survival in AIDS-patients with leukopenia and CD4 cells less than 50 x 106/l.
-
Filgrastim (r-met-HuG-CSF) for prevention of severe neutropenia and associated clinical sequelae in HIV-infected patients: results of a 24-week, prospective, randomized, controlled trial.
-
Filgrastim (r-methug-CSF) treatment of HIV-infected patients improves neutrophil function.
-
Filgrastim in Georgian HIV Patients with Bacterial Infections with or without Neutropenia.
-
Filgrastim Stimulates HIV-1 Replication in Monocytoid Cells.
-
Filgrastim, CEOP and antiretroviral therapy in HIV-related non-Hodgkins lymphoma (NHL).
-
Filipino PWHIV/PWAIDS' struggle for life.
-
Filipinos living with HIV/AIDS: A voice for self-healing and access to treatment.
-
Filling in the Gap with Public/Private Partnerships: Local Three Share Initiatives to Cover the Uninsured.
-
Filling the gap between homeless life and the conventional health system.
-
Filling the void: Exploring young heterosexual males' absence in HIV/AIDS prevention programs in Halifax, NS Canada.
-
Filters for crack users: a new harm reduction strategy in Santos, Brazil.
-
Fim-H-based Vaccine for Prevention of Escherichia coli Urinary Tract Infections.
-
Final 144 week resistance analysis for treatment-Naive patients Taking Tenofovir DF (TDF) or Stavudine (d4T) in combination with Lamivudine (3TC) and Efavirenz (EFV).
-
Final 48-Week Genotypic and Phenotypic Analyses of Study 907: Tenofovir DF (TDF) Added to Stable Background Regimens.
-
Final 48-week results of a phase II, randomized study of the safety, efficacy, and pharmacokinetics of BID vs TID nelfinavir and saquinavir in combination with lamivudine and stavudine in HIV- positive women (women first trial).
-
Final 54-Week Analysis of a Placebo-Controlled Trial (13C) of Delavirdine (DLV) Plus Two Nucleoside Analogs (NA) Versus Two NA in Drug-Naive and -Experienced Individuals.
-
Final analysis of a prospective, randomized, open-label, muticentre trial in naive, HIV-1-infected patients, comparing ZDV/3TC vs d4T/ddI, plus Efavirenz, Nevirapine or Indinavir/Ritonavir (AMADEUS 01 study).